$3.46
-0.12 (-3.35%)
Open$3.64
Previous Close$3.58
Day High$3.78
Day Low$3.46
52W High$7.20
52W Low$3.10
Volume—
Avg Volume65.4K
Market Cap6.90M
P/E Ratio—
EPS$-16.44
SectorBiotechnology
Analyst Ratings
Buy
10 analysts
Price Target
+662.1% upside
Current
$3.46
$3.46
Target
$26.37
$26.37
$21.16
$26.37 avg
$30.50
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 7.93M | 7.18M | 3.98M |
| Net Income | -34,383,133 | -28,047,511 | 267.7K |
| Profit Margin | -433.7% | -412.1% | 6.7% |
| EBITDA | -35,872,776 | -30,888,368 | 477.9K |
| Free Cash Flow | — | — | 225.1K |
| Rev Growth | +10.3% | +10.3% | +11.2% |
| Debt/Equity | — | — | 0.39 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |